Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CADM1-GGFG-exatecan
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CADM1-GGFG-exatecan is an antibody-drug conjugate (ADC) designed to target Cell Adhesion Molecule 1 (CADM1), a cell-surface protein identified as a promising therapeutic target in osteosarcoma. The ADC consists of a monoclonal antibody specific for CADM1 conjugated to the potent DNA topoisomerase I inhibitor exatecan via a protease-cleavable GGFG (glycyl-glycyl-phenylalanyl-glycyl) linker. This specific linker-payload configuration is optimized for efficient internalization and lysosomal processing within tumor cells. Preclinical studies in patient-derived xenograft (PDX) models of osteosarcoma have demonstrated that CADM1-GGFG-exatecan possesses superior anti-tumor activity and internalization kinetics compared to other linker variants, such as those utilizing PEG3-VC structures. It has shown the ability to induce maintained complete responses and significantly prolong event-free survival in various osteosarcoma models.
- Other names
- CADM1-GGFG-ExatecanCADM-1-GGFG-ExatecanCADM 1-GGFG-Exatecan
02
Targets
TOP1 (DNA Topoisomerase I)CADM1 (Cell adhesion molecule 1)
Beyond the preview
Go deeper on CADM1-GGFG-exatecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CADM1-GGFG-exatecan.